Navigation Links
Immatics Implements Genedata Biologics® into Proprietary T-Cell Receptor Discovery and Engineering XCEPTOR® Platform
Date:11/12/2019

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies, a clinical-stage biopharmaceutical company developing T-cell receptor (TCR)-based cancer immunotherapies, has adopted Genedata Biologics® to streamline their R&D operations related to the discovery and development of high-affinity and high-specificity T-cell receptors for adoptive cell therapies (ACT) and bispecific TCRs.

“We required a scalable software solution that is compatible with Immatics’ proprietary XCEPTOR® platform to facilitate the systematic analysis of our TCR data for our proprietary and partnered programs,” said Dominik Maurer, Ph.D., VP Immunology at Immatics. “Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow, including Immatics’ ACTengine®, ACTallo® and TCER® bispecific TCR molecule development. We expect Genedata Biologics to foster our internal information exchange and further increase our efficiency.”

Integrated E2E Workflow Platform for Cell & Gene Therapy
As highly engineered entities, bispecific molecules and cell and gene therapies pose new design, cloning, expression, purification, and analytics challenges. Genedata Biologics provides purpose-built functionality for the design and evaluation of large panels of novel cellular modalities, such as engineered TCRs and their variations. In particular, the platform enables the automation of screening, engineering, production, and testing of these innovative therapeutic modalities. The workflow platform handles next-generation molecule-specific designs in high throughput and includes dedicated tools for developability and manufacturability assessments. Genedata Biologics is an end-to-end (E2E) platform that streamlines the design, generation, validation, and unique identification of TCR- based molecules, resulting in more efficient evaluation and production.

“We are excited that Immatics, a leader in immuno-oncology, has selected Genedata as their partner,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are delighted that Genedata Biologics helps our customers to increase the efficiency of the discovery and development of novel gene and cellular therapeutics, and we will continue to invest in expanding the platform’s capabilities to address new technologies and requirements in this quickly evolving field.”

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
http://www.genedata.com
LinkedIn | Twitter | YouTube

Contact
Miles Fisher-Pollard
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at https://www.prweb.com/releases/immatics_implements_genedata_biologics_into_proprietary_t_cell_receptor_discovery_and_engineering_xceptor_platform/prweb16713446.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
2. Sarah Cannon Research Institute Implements Virtify CTRR
3. Life Science Equipment Manufacturer and Distributor Implements Accounts Receivable Collections Software for Sage 100 ERP
4. Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
5. Lajollacooks4u Implements Popular New Team Building Format
6. Sigma Blood Systems Implements PERFEQTA Software With Central Jersey Blood Center
7. Jupiter Medical Center Implements Revolutionary Watson for Oncology to Help Oncologists Make Data-Driven Cancer Treatment Decisions
8. Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials
9. Yale New Haven Health System Implements ActX Genomic Decision Support Within Epic
10. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
11. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2020)... ... , ... QCDx , a private biotech company that has developed a ... the sale of the proprietary RareScope™ instrument to the Carole and Ray Neag Comprehensive ... research. , “The RareScope can detect and isolate intact and live Circulating Tumor Cells ...
(Date:1/10/2020)... (PRWEB) , ... January 09, 2020 , ... ... and expert services, today announced the acquisition of Cunesoft, a move that expands ... the business objectives of life sciences companies. , Based in Munich, Germany, Cunesoft ...
(Date:1/8/2020)... , ... January 08, 2020 , ... ... wire composites that can achieve specific properties for use in harsh environments inside ... Wire combines up to three metals or alloys to achieve specific properties ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo ... obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant ...
Breaking Biology Technology:
(Date:1/24/2020)... ... 24, 2020 , ... The Rockies Venture Club and Colorado ... early-stage bioscience companies in the state. , “Colorado has a world-class ... they need to innovate and grow. This program will mobilize capital within ...
(Date:1/22/2020)... (PRWEB) , ... January 21, 2020 , ... ... Pozil to lead the company’s new Business Development Department. The move, which is ... Pozil had been previously serving as the company’s Senior Vice President where he ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... prospectus. The Lifecycle prospectus features not just part numbers like what can be ... facilities, the industries it supports, and that is all linked to the impact ...
Breaking Biology News(10 mins):